Literature DB >> 25492084

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.

Michaela K Keck1, Zhixiang Zuo2, Arun Khattri2, Thomas P Stricker3, Christopher D Brown4, Matin Imanguli5, Damian Rieke2, Katharina Endhardt2, Petra Fang2, Johannes Brägelmann2, Rebecca DeBoer2, Mohamed El-Dinali2, Serdal Aktolga2, Zhengdeng Lei6, Patrick Tan7, Steve G Rozen6, Ravi Salgia8, Ralph R Weichselbaum8, Mark W Lingen9, Michael D Story10, K Kian Ang11, Ezra E W Cohen12, Kevin P White13, Everett E Vokes8, Tanguy Y Seiwert14.   

Abstract

PURPOSE: Current classification of head and neck squamous cell carcinomas (HNSCC) based on anatomic site and stage fails to capture biologic heterogeneity or adequately inform treatment. EXPERIMENTAL
DESIGN: Here, we use gene expression-based consensus clustering, copy number profiling, and human papillomavirus (HPV) status on a clinically homogenous cohort of 134 locoregionally advanced HNSCCs with 44% HPV(+) tumors together with additional cohorts, which in total comprise 938 tumors, to identify HNSCC subtypes and discover several subtype-specific, translationally relevant characteristics.
RESULTS: We identified five subtypes of HNSCC, including two biologically distinct HPV subtypes. One HPV(+) and one HPV(-) subtype show a prominent immune and mesenchymal phenotype. Prominent tumor infiltration with CD8(+) lymphocytes characterizes this inflamed/mesenchymal subtype, independent of HPV status. Compared with other subtypes, the two HPV subtypes show low expression and no copy number events for EGFR/HER ligands. In contrast, the basal subtype is uniquely characterized by a prominent EGFR/HER signaling phenotype, negative HPV-status, as well as strong hypoxic differentiation not seen in other subtypes.
CONCLUSION: Our five-subtype classification provides a comprehensive overview of HPV(+) as well as HPV(-) HNSCC biology with significant translational implications for biomarker development and personalized care for patients with HNSCC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25492084     DOI: 10.1158/1078-0432.CCR-14-2481

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  129 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

Review 2.  [Human papillomavirus and squamous cell cancer of the head and neck region : Prognostic, therapeutic and prophylactic implications].

Authors:  M Reuschenbach; S Wagner; N Würdemann; S J Sharma; E-S Prigge; M Sauer; A Wittig; C Wittekindt; M von Knebel Doeberitz; J P Klussmann
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 3.  Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer.

Authors:  Farhoud Faraji; Munfarid Zaidi; Carole Fakhry; Daria A Gaykalova
Journal:  Microbes Infect       Date:  2017-06-12       Impact factor: 2.700

4.  Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.

Authors:  Lei Huang; Odile David; Robert J Cabay; Klara Valyi-Nagy; Virgilia Macias; Rong Zhong; Barry Wenig; Lawrence Feldman; Ralph Weichselbaum; Michael T Spiotto
Journal:  Clin Cancer Res       Date:  2018-12-20       Impact factor: 12.531

5.  Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response.

Authors:  C Cleary; J E Leeman; D S Higginson; N Katabi; E Sherman; L Morris; S McBride; N Lee; N Riaz
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-04-01       Impact factor: 4.126

6.  Histologic pattern of invasion and epithelial-mesenchymal phenotype predict prognosis in squamous carcinoma of the head and neck.

Authors:  Gregory T Wolf; William Winter; Emily Bellile; Ariane Nguyen; C R Donnelly; Jonathan B McHugh; Dafydd Thomas; Lahin Amlani; Laura Rozek; Yu L Lei
Journal:  Oral Oncol       Date:  2018-10-22       Impact factor: 5.337

7.  The Immune Subtypes and Landscape of Squamous Cell Carcinoma.

Authors:  Bailiang Li; Yi Cui; Dhanya K Nambiar; John B Sunwoo; Ruijiang Li
Journal:  Clin Cancer Res       Date:  2019-03-04       Impact factor: 12.531

8.  Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.

Authors:  Jessica Ley; Tanya M Wildes; Kristin Daly; Peter Oppelt; Douglas Adkins
Journal:  Med Oncol       Date:  2017-01-11       Impact factor: 3.064

Review 9.  [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].

Authors:  G Wichmann; A Dietz
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

10.  AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.

Authors:  Caterina Peraldo-Neia; Paola Ostano; Maurizia Mello-Grand; Francesca Guana; Ilaria Gregnanin; Donatella Boschi; Simonetta Oliaro-Bosso; Agnese Chiara Pippione; Andrea Carenzo; Loris De Cecco; Stefano Cavalieri; Arianna Micali; Federica Perrone; Gianluca Averono; Paolo Bagnasacco; Riccardo Dosdegani; Laura Masini; Marco Krengli; Paolo Aluffi-Valletti; Guido Valente; Giovanna Chiorino
Journal:  Cell Oncol (Dordr)       Date:  2020-11-19       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.